The following two weeks we will be discussing the clinical preventive service and our role on disease prevention. A valuable website to review the screening prevention recommendations based on the latest evidence based practice : On your discussion this week answer the following questions: 1.) What is the U.S. Preventive Task Force (USPTF)? 2. ) Select a disease for example colon cancer and discuss the screening age recommendations and the screening tools recommended for early prevention?

The United States Preventive Services Task Force (USPSTF) is an independent, volunteer panel of experts in prevention and evidence-based medicine. It was established in 1984 and is sponsored by the Agency for Healthcare Research and Quality (AHRQ). The primary objective of the USPSTF is to make evidence-based recommendations regarding clinical preventive services, including screenings, counseling, and preventive medications.

The USPSTF conducts systematic reviews of the available evidence on various preventive services and establishes grades based on the strength of the evidence. The grades range from “A” to “D” and “I”, which respectively indicate strong evidence in favor of, moderate evidence in favor of, insufficient evidence to assess, and evidence against a preventive service.

Now, let’s examine the screening recommendations for colon cancer, which is a common example of a disease for early prevention through screening. According to the USPSTF, regular screening for colorectal cancer should begin at age 50 and continue until the age of 75 for individuals at average risk. However, the task force recognizes that the risk of colorectal cancer increases with age, and therefore, the decision to continue screening beyond age 75 should be based on individual patient preferences, overall health status, and prior screening history.

There are several different screening tools recommended for early prevention and detection of colon cancer. The USPSTF has identified three main types of screening modalities: stool-based tests, structural examinations, and combined tests.

1. Stool-based tests: These tests detect the presence of blood or certain DNA markers in the stool, which may indicate the presence of precancerous or cancerous cells. The USPSTF recommends two types of stool-based tests:

a) Fecal occult blood test (FOBT) – This test is performed annually and involves collecting multiple stool samples at home and submitting them for lab analysis. If blood is found in the stool, further diagnostic procedures, such as a colonoscopy, may be required for confirmation.

b) Fecal immunochemical test (FIT) – This is another annual test that detects blood in the stool. It is a more specific and sensitive test than FOBT and does not require dietary restrictions before the test.

2. Structural examinations: These tests directly visualize the inside of the colon to detect abnormalities. The USPSTF recommends two types of structural examinations:

a) Colonoscopy – This is considered the “gold standard” for colon cancer screening. It involves inserting a flexible tube with a camera into the rectum and advancing it through the entire colon. If polyps or abnormal tissue are detected, they can be removed during the procedure.

b) Flexible sigmoidoscopy – This screening test examines the lower part of the colon using a flexible tube with a camera. It is usually performed every 5 years and may be combined with a stool-based test for more comprehensive screening.

3. Combined tests: These tests combine both stool-based and structural examinations. The USPSTF recommends one type of combined test:

a) CT colonography – Also known as virtual colonoscopy, this test uses computed tomography to create detailed images of the colon. It is typically performed every 5 years and, if abnormalities are found, a follow-up colonoscopy is necessary for further evaluation or treatment.

In conclusion, the USPSTF plays a critical role in providing evidence-based recommendations for clinical preventive services. For colon cancer screening, the task force recommends regular screenings starting at age 50 for individuals at average risk. The recommended screening tools include stool-based tests (FOBT and FIT), structural examinations (colonoscopy and flexible sigmoidoscopy), and combined tests (CT colonography). However, it is important to note that these recommendations may vary based on individual patient factors, including age, overall health status, and prior screening history. Therefore, it is essential to consult with healthcare providers to determine the most appropriate screening approach for each individual.